Charles River offers state-of-the-art screening platform technologies for the identification of hit compounds using our own libraries, or those of our clients. We deliver validated hit compounds from more than 20 high-throughput screening (HTS) campaigns per year.

Our HTS facility is supported by a team of 50 scientists with an average of 10 years of experience in HTS and hit finding technologies from the pharmaceutical industry. We are well-equipped and experienced in addressing challenging targets and assay systems. Our robust quality management system (QMS) and assay validation procedures generate high quality data, which is processed through IDBS, Titian, and Dotmatics software suites to ensure we transfer accurate and confidential information to you.

We are also able to provide compound screening services for client libraries with a capacity of up to 1 million compounds in single compound format or up to 3 million in compressed formats, with the ability to store a copy of your library for multiple screening campaigns.

Ask us a question about your screen

High-Throughput Mass Spectrometry

High-throughput mass spectrometry (HTMS) has become an indispensable tool for hit identification. By eliminating artifacts introduced by fluorescent tags, these label-free biochemical and cell-based screens generate rich, multi-parametric data that are highly reproducible and contain very few false positives.

HTMS is applied in screening, hit confirmation and ADME, offering the advantage of direct detection without the use of surrogates, radioactivity or coupled assays.

Charles River offers HTMS on high-capacity equipment paired with the added flexibility of column chromatography.

Hit Expansion

Our hit expansion process is a highly cost-effective way to further enlarge the pool of active compounds following a screen and to gain early structure-activity relationship (SAR) data.

By examining chemical motifs and scaffolds found to have activity in the primary screen, we can mine our extensive compound collection and select sets of related compounds for follow-on screening. This helps to rapidly identify additional hits and new scaffolds as well as to build SAR around existing hits. These additional compound sets are identified using 2D and 3D similarity and pharmacophore searching.